Somatic mutations also contribute to melanoma development and progression, with alterations in the mitogen-activated protein kinase (MAPK) signalling cascade representing a key pathogenic pathway present in about 90% of cutaneous melanomas [15]. The gene discussed is WNK2; the disease is cutaneous melanoma.